tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Mar 3;10(3):393.
doi: 10.3390/vaccines10030393.
COVID-19 Vaccine Effectiveness: A Review of the First 6 Months of COVID-19 Vaccine Availability (1 January-30 June 2021)
Sarah M Hatcher[SUP] 1 [/SUP], Stacy M Endres-Dighe[SUP] 1 [/SUP], Frederick J Angulo[SUP] 2 [/SUP], Amit Srivastava[SUP] 2 [/SUP], Jennifer L Nguyen[SUP] 2 [/SUP], Farid Khan[SUP] 2 [/SUP], Catherine Martin[SUP] 2 [/SUP], David L Swerdlow[SUP] 2 [/SUP], John M McLaughlin[SUP] 2 [/SUP], Nneka Ubaka-Blackmore[SUP] 1 [/SUP], Linda Morris Brown[SUP] 1 [/SUP]
Affiliations
Abstract
Observational studies are needed to demonstrate real-world vaccine effectiveness (VE) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outcomes. Our objective was to conduct a review of published SARS-CoV-2 VE articles, supplemented by preprints, during the first 6 months of COVID-19 vaccine availability. This review compares the effectiveness of completing the primary COVID-19 vaccination series against multiple SARS-CoV-2 disease presentations and disease severity outcomes in three population groups (general population, frontline workers, and older adults). Four hundred and seventy-one published articles and 47 preprints were identified. After title and abstract screening and full article review, 50 studies (28 published articles, 22 preprints) were included. VE results were reported for five COVID-19 vaccines and four combinations of COVID-19 vaccines. VE results for BNT162b2 were reported in 70.6% of all studies. Seventeen studies reported variant specific VE estimates; Alpha was the most common. This comprehensive review demonstrates that COVID-19 vaccination is an important tool for preventing COVID-19 morbidity and mortality among fully vaccinated persons aged 16 years and older and serves as an important baseline from which to follow future trends in COVID-19 evolution and effectiveness of new and updated vaccines.
Keywords: Ad26.COV2.S; BNT162b2 vaccine; COVID-19 vaccines; ChAdOx1 nCoV-19; SARS-CoV-2; mRNA-1273 vaccine; observational studies; review literature; vaccine effectiveness.
. 2022 Mar 3;10(3):393.
doi: 10.3390/vaccines10030393.
COVID-19 Vaccine Effectiveness: A Review of the First 6 Months of COVID-19 Vaccine Availability (1 January-30 June 2021)
Sarah M Hatcher[SUP] 1 [/SUP], Stacy M Endres-Dighe[SUP] 1 [/SUP], Frederick J Angulo[SUP] 2 [/SUP], Amit Srivastava[SUP] 2 [/SUP], Jennifer L Nguyen[SUP] 2 [/SUP], Farid Khan[SUP] 2 [/SUP], Catherine Martin[SUP] 2 [/SUP], David L Swerdlow[SUP] 2 [/SUP], John M McLaughlin[SUP] 2 [/SUP], Nneka Ubaka-Blackmore[SUP] 1 [/SUP], Linda Morris Brown[SUP] 1 [/SUP]
Affiliations
- PMID: 35335025
- DOI: 10.3390/vaccines10030393
Abstract
Observational studies are needed to demonstrate real-world vaccine effectiveness (VE) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outcomes. Our objective was to conduct a review of published SARS-CoV-2 VE articles, supplemented by preprints, during the first 6 months of COVID-19 vaccine availability. This review compares the effectiveness of completing the primary COVID-19 vaccination series against multiple SARS-CoV-2 disease presentations and disease severity outcomes in three population groups (general population, frontline workers, and older adults). Four hundred and seventy-one published articles and 47 preprints were identified. After title and abstract screening and full article review, 50 studies (28 published articles, 22 preprints) were included. VE results were reported for five COVID-19 vaccines and four combinations of COVID-19 vaccines. VE results for BNT162b2 were reported in 70.6% of all studies. Seventeen studies reported variant specific VE estimates; Alpha was the most common. This comprehensive review demonstrates that COVID-19 vaccination is an important tool for preventing COVID-19 morbidity and mortality among fully vaccinated persons aged 16 years and older and serves as an important baseline from which to follow future trends in COVID-19 evolution and effectiveness of new and updated vaccines.
Keywords: Ad26.COV2.S; BNT162b2 vaccine; COVID-19 vaccines; ChAdOx1 nCoV-19; SARS-CoV-2; mRNA-1273 vaccine; observational studies; review literature; vaccine effectiveness.